



**NOTICE OF ANNUAL MEETING OF SHAREHOLDERS**

**AND MANAGEMENT PROXY CIRCULAR**

**Annual Meeting – June 29, 2011**

**NOTICE OF ANNUAL MEETING OF SHAREHOLDERS OF WARNEX INC.**


NOTICE IS HEREBY GIVEN that an annual meeting of the shareholders of Warnex Inc. (the "Corporation") will be held at the Hotel Hilton, 2225 Autoroute des Laurentides, Laval, Quebec, "Salon Tétreault", at the hour of 11:00 a.m., Montreal time, on Wednesday, June 29, 2011, for the following purposes:

1. To receive the report of management and the consolidated financial statements of the Corporation for the year ended December 31, 2010, together with the auditors' report thereon;
2. To elect the Directors of the Corporation for the ensuing year;
3. To appoint the auditors for the ensuing year and to authorize the Directors to fix their remuneration; and
4. To transact such other business as may properly be brought before the meeting or any adjournment thereof.

The enclosed Management Proxy Circular should be consulted for further details on the matters to be acted upon. A copy of a Form of Proxy for the meeting is attached with this Notice.

DATED at Laval, Quebec this 17th day of May, 2011.

BY ORDER OF THE BOARD OF DIRECTORS



Mark Busgang  
President and CEO

**IMPORTANT**

Only holders of common shares of the Corporation of record at the close of business on May 26, 2011 are entitled to receive a notice of the Meeting and only those holders of the common shares of the Corporation of record at the close of business on May 26, 2011, or who subsequently become shareholders and comply with the provisions of the *Canada Business Corporations Act* are entitled to vote at the Meeting. If you are unable to attend in person, kindly fill in, sign and return the enclosed proxy in the envelope provided for that purpose.

Proxies, to be valid, must be deposited at the office of the registrar and transfer agent of the Corporation, Computershare Trust Company of Canada (Attention: Proxy Department), 9th Floor, 100 University Avenue, Toronto, Ontario, M5J 2Y1, not less than 48 hours, excluding Saturdays, Sundays and statutory holidays, preceding the meeting or adjournment of the meeting.

**TABLE OF CONTENTS**

**A. VOTING INFORMATION**

Purpose of Solicitation	Page 1
Voting of Proxies	Page 1
Appointment of Proxy	Page 1
Revocation of Proxies	Page 2
Advice to Beneficial Holders of Common Shares on Voting Common Shares	Page 2
Voting Shares and Principal Holders Thereof	Page 3

**B. BUSINESS OF THE ANNUAL MEETING**

Election of Directors	Page 4
Appointment of Auditors	Page 4
Shareholder Proposals	Page 4

**C. BOARD OF DIRECTORS**

Biographies	Page 4
-------------	--------

**D. DISCLOSURE OF COMPENSATION AND OTHER INFORMATION**

Compensation of Directors	Page 8
Compensation of Executive Officers	Page 11
Compensation Discussion and Analysis	Page 11
Outstanding Option-Based Awards	Page 15
Summary Compensation Table	Page 16
Termination and Change of Control Benefits	Page 18
Performance Graph	Page 19
Equity Compensation Plans	Page 20

**E. OTHER INFORMATION**

Report of the Corporate Governance Committee	Page 21
Directors' and Officers' Liability Insurance	Page 26
Interest of Certain Persons in Matters to be Acted Upon	Page 26
Indebtedness of Directors and Officers	Page 26
Interest of Insiders in Material Transactions	Page 26
General	Page 27
Additional Information	Page 27
Approval of the Directors	Page 27

## **MANAGEMENT PROXY CIRCULAR**

### **A. VOTING INFORMATION**

#### **PURPOSE OF SOLICITATION**

**THIS MANAGEMENT PROXY CIRCULAR (THE “INFORMATION CIRCULAR”) IS FURNISHED IN CONNECTION WITH THE SOLICITATION OF PROXIES BY THE MANAGEMENT OF WARNEX INC. (THE “CORPORATION”) FOR USE AT THE ANNUAL MEETING OF SHAREHOLDERS OF THE CORPORATION TO BE HELD AT THE HOTEL HILTON, 2225 AUTOROUTE DES LAURENTIDES, LAVAL, QUEBEC, “SALON TÉTREAUULT”, ON WEDNESDAY, JUNE 29, 2011, AT THE HOUR OF 11:00 O’CLOCK A.M., MONTREAL TIME, AND AT ANY ADJOURNMENTS THEREOF FOR THE PURPOSES SET OUT IN THE ACCOMPANYING NOTICE OF MEETING.** Although it is expected that the solicitation of proxies will be primarily by mail, proxies may also be solicited by the Management of the Corporation by telephone, fax or personal interviews. The cost of any such solicitation will be borne by the Corporation.

#### **VOTING OF PROXIES**

All Common Shares represented at the meeting by properly executed proxies will be voted and where a choice with respect to any matter to be acted upon has been specified in the instrument of proxy, the Common Shares represented by the proxy will be voted in accordance with such specifications. **IN THE ABSENCE OF ANY SUCH SPECIFICATIONS, THE MANAGEMENT DESIGNEES, IF NAMED AS PROXY, WILL VOTE IN FAVOUR OF ALL THE MATTERS SET OUT HEREIN.**

**THE ENCLOSED INSTRUMENT OF PROXY CONFERS DISCRETIONARY AUTHORITY UPON THE MANAGEMENT DESIGNEES, OR OTHER PERSONS NAMED AS PROXY, WITH RESPECT TO AMENDMENTS TO OR VARIATIONS OF MATTERS IDENTIFIED IN THE NOTICE OF MEETING AND ANY OTHER MATTERS WHICH MAY PROPERLY COME BEFORE THE MEETING. AT THE DATE OF THIS INFORMATION CIRCULAR, THE CORPORATION IS NOT AWARE OF ANY AMENDMENTS TO, OR VARIATIONS OF, OR OTHER MATTERS, WHICH MAY COME BEFORE THE MEETING. IN THE EVENT THAT OTHER MATTERS COME BEFORE THE MEETING, THEN THE MANAGEMENT DESIGNEES INTEND TO VOTE IN ACCORDANCE WITH THE JUDGEMENT OF THE MANAGEMENT OF THE CORPORATION.**

Proxies, to be valid, must be deposited at the offices of the registrar and transfer agent of the Corporation, Computershare Trust Company of Canada (Attention: Proxy Department), 9th Floor, 100 University Avenue, Toronto, Ontario, M5J 2Y1, not less than 48 hours, excluding Saturdays, Sundays and statutory holidays, preceding the meeting or an adjournment of the meeting.

#### **APPOINTMENT OF PROXY**

**A SHAREHOLDER HAS THE RIGHT TO DESIGNATE A PERSON (WHO NEED NOT BE A SHAREHOLDER OF THE CORPORATION) OTHER THAN MARK BUSGANG AND RICHARD LAFERRIÈRE, THE MANAGEMENT DESIGNEES, TO ATTEND AND ACT FOR HIM AT THE MEETING.** Such right may be exercised by inserting in the blank space provided, the name of the person to be designated and deleting therefrom the names of the management designees or by completing another proper instrument of proxy and, in either case, depositing the instrument of proxy at the offices of the registrar and transfer agent of the Corporation, Computershare Trust Company of Canada (Attention: Proxy Department), 9th Floor, 100 University Avenue, Toronto, Ontario, M5J 2Y1, not less than 48 hours, excluding Saturdays, Sundays and statutory holidays, preceding the meeting or an adjournment of the meeting.

## REVOCATION OF PROXIES

A shareholder who has given a proxy may revoke it as to any matter upon which a vote has not already been cast pursuant to the authority conferred by the proxy.

A shareholder may revoke a proxy by depositing an instrument in writing, executed by him or his attorney authorized in writing:

- (1) at the offices of the registrar and transfer agent of the Corporation, Computershare Trust Company of Canada (Attention: Proxy Department), 9th Floor, 100 University Avenue, Toronto, Ontario, M5J 2Y1, at any time, not less than 48 hours, excluding Saturdays, Sundays and statutory holidays, preceding the meeting or adjournment of the meeting at which the proxy is to be used; or
- (2) at the registered office of the Corporation, 3885 Industriel Blvd, Laval, Quebec, H7L 4S3, to the attention of the Corporate Secretary at any time up to and including the last business day preceding the day of the meeting at which the proxy is to be used; or
- (3) with the Chairman of the meeting on the day of the meeting or an adjournment of the meeting.

In addition, a proxy may be revoked by the shareholder executing another form of proxy bearing a later date and depositing same at the offices of the registrar and transfer agent of the Corporation within the time period set out under the heading "VOTING OF PROXIES", or by the shareholder personally attending the meeting and voting his shares.

## ADVICE TO BENEFICIAL HOLDERS OF COMMON SHARES ON VOTING COMMON SHARES

**The information set forth in this section is of significant importance to many shareholders of the Corporation, as a substantial number of shareholders do not hold Common Shares of the Corporation (the "Common Shares") in their own name.** Shareholders who do not hold their shares in their own name (referred to in this Information Circular as "Beneficial Shareholders") should note that only proxies deposited by shareholders whose names appear on the records of the Corporation as the registered holders of Common Shares can be recognized and acted upon at the Meeting. If Common Shares are listed in an account statement provided to a shareholder by a broker, then, in almost all cases, those Common Shares will not be registered in the shareholder's name on the records of the Corporation. Such Common Shares are likely to be registered under the name of the shareholder's broker or an agent of that broker. Common Shares held by brokers or their agents or nominees can only be voted (for or against resolutions) upon the instructions of the Beneficial Shareholder. Without specific instructions, a broker and its agents and nominees are prohibited from voting shares for the broker's clients. **Therefore, Beneficial Shareholders should ensure that instructions respecting the voting of their Common Shares are communicated to the appropriate person.**

Applicable regulatory rules require intermediaries/brokers to seek voting instructions from Beneficial Shareholders in advance of shareholders' meetings. Every intermediary/broker has its own mailing procedures and provides its own return instructions to clients, which should be carefully followed by Beneficial Shareholders in order to ensure that their Common Shares are voted at the Meeting. Often, the form of proxy supplied to a Beneficial Shareholder by its broker (or the agent of the broker) is identical to the form of proxy provided to registered shareholders. However, its purpose is limited to instructing the registered shareholder (the broker or agent of the broker) how to vote on behalf of the Beneficial Shareholder. **A Beneficial Shareholder receiving a proxy from an intermediary cannot use that proxy to vote Common Shares directly at the Meeting. The proxy must be returned to the intermediary well in advance of the Meeting in order to have the Common Shares voted at the Meeting.**

Although a Beneficial Shareholder may not be recognized directly at the Meeting for the purposes of voting Common Shares registered in the name of his or her broker (or an agent of the broker), a Beneficial Shareholder may attend the Meeting as proxy holder for the registered shareholder and vote the Common Shares in that capacity. Beneficial Shareholders who wish to attend the Meeting and indirectly vote their Common Shares as proxy holder for the registered shareholder, should enter their own names in the blank space on the form of proxy provided to them and return same to their broker (or the broker's agent) in accordance with the instructions provided by such broker (or agent), well in advance of the Meeting.

#### **VOTING SHARES AND PRINCIPAL HOLDERS THEREOF**

The Corporation is authorized to issue an unlimited number of Common Shares and an unlimited number of preferred shares, without nominal or par value, of which 67,117,191 Common Shares were issued and outstanding as of May 17, 2011, and entitled to vote at the meeting on the basis of one vote for each Common Share held.

The holders of Common Shares of record at the close of business on the record date, set by the Directors of the Corporation to be May 26, 2011, are entitled to vote such Common Shares at the meeting, except to the extent that:

- (1) such person transfers his shares after the record date; and
- (2) the transferee of those shares produces properly endorsed share certificates or otherwise establishes his ownership to the shares;

and makes a demand to the registrar and transfer agent of the Corporation, not later than 10 days before the meeting, that his name be included on the shareholders' list.

The by-laws of the Corporation provide that two (2) persons present and representing in person or by proxy not less than 10% of the issued shares entitled to vote at the meeting constitute a quorum for the meeting.

To the knowledge of the Directors and officers of the Corporation, the only persons who beneficially own, directly or indirectly, or controls or directs, Common Shares carrying more than 10% of the voting rights of the outstanding Common Shares of the Corporation are the following:

#### **PRINCIPAL HOLDERS OF SHARES**

<b>Name</b>	<b>Number of Common Shares</b>	<b>Percentage of Outstanding Common Shares</b>
Persistence Capital Partners LP	12,238,750	18.2%

#### **B. BUSINESS OF THE ANNUAL MEETING**

To the knowledge of the Corporation's Directors, the only matters to be placed before the meeting are those matters set forth in the accompanying notice of meeting relating to the receipt of the management report and the financial statements, the election of the Directors and the appointment of the auditors.

## **ELECTION OF DIRECTORS**

The Articles of the Corporation stipulate that the Board of Directors shall consist of a minimum of three (3) Directors and a maximum of fifteen (15) Directors. Management proposes that the five (5) actual members of the Board of Directors and the four (4) new Board candidates presented in this Information Circular be elected to hold office until the next annual meeting of shareholders or until his or her successor is duly elected or appointed pursuant to the by-laws of the Corporation. Please refer to Section C Board of Directors for each nominee's biography.

**It is the intention of the management designees, if named as proxy, to vote for the election of said persons to the Board of Directors. Management does not contemplate that any of such nominees will be unable to serve as Directors. However, if, for any reason, any of the proposed nominees do not stand for election or are unable to serve as such, proxies in favour of management designees will be voted for another nominee at their discretion unless the shareholder has specified in his proxy that his shares are to be withheld from voting in the election of Directors.**

## **APPOINTMENT OF AUDITORS**

**The management designees, if named as proxy, intend to vote the Common Shares represented by any such proxy for the appointment of Nexia Friedman, chartered accountants, as auditors of the Corporation at a remuneration to be fixed by the Board of Directors unless the Shareholder has specified in his proxy that his shares are to be withheld from voting in the election of auditors.** Nexia Friedman, Chartered Accountants have been the auditors of the Corporation since May 19, 1998. The auditors will hold office until the next Annual Meeting of Shareholders or until their successors are appointed.





## **SHAREHOLDER PROPOSALS**





Shareholders who wish to submit a proposal for consideration at the next meeting to be held in 2012 must do so by submitting them to the attention of the Secretary of the Corporation on or before February 17, 2012, in the manner and subject to the limitations prescribed by the Canada Business Corporation Act.


## **C. BOARD OF DIRECTORS**

### **BIOGRAPHIES**

The following table sets forth, for each person nominated by management for election as a Director, his name, province or state and country of residence, the year in which he first became a Director, his principal occupation for the last five years, his Committee memberships, the number of Common Shares of the Corporation beneficially owned, directly or indirectly, or over which control or direction was exercised and the number of stock options in the Corporation held, all as at May 17, 2011.

 <p><b>Richard Laferrière, 56</b> Quebec, Canada Shares: 750,000 Options: 146,899</p>	<p>Mr. Laferrière has been Executive Chairman of Extenway Solutions Inc.(TSX-V), a company offering multimedia and connectivity solutions to the health sector since May 2008. He was Chairman of the Board of FRV Media Inc. from May 2008 to November 2010. From 1998 to 2008, Mr. Laferrière was President and Chief Executive Officer as well as Director of FRV Media Inc. He was co-founder and President of Groupe Coscient from 1978 to 1999. In 2007, Mr. Laferrière joined the Board of Directors of Fronsac Capital Inc. Mr. Laferrière was a director of GDG Environment Group Ltd until October 2010.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• Chairman of the Board of Directors since 1996</li> <li>• Member of the Corporate Governance Committee (Chair)</li> <li>• Independent director</li> </ul>
 <p><b>Mark Busgang, 55</b> Quebec, Canada Shares: 5,739,400<sup>(1)</sup></p>	<p>Mr. Busgang has served on the Corporation's Board and has been President and Chief Executive Officer of the Corporation since February 1998. From 1993 to 1996, he was President of Pharmetics Ltd., Vice President of Operations of Theratechnologies Inc. and a director of Theratechnologies Inc. Mr. Busgang is currently on the board of directors of ETS (École de technologie supérieure), of CLSC Cavendish, of Laval Technopole and of BioQuebec. He holds an MBA from Fordham University.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• Director since 1998</li> <li>• Related director due to his position as President and CEO of the Corporation</li> </ul>
 <p><b>Louis Lacasse, 54</b> Quebec, Canada Shares: 45,000 Options: 130,499</p>	<p>Mr. Lacasse has been President of GeneChem Management Inc. since 1997 and Managing Partner of AgeChem Financial Inc. since 2006. Mr. Lacasse is currently on the boards of directors of Methylgene Inc. and Calyx Bioventures. He has previously served on the boards of directors of many private and public companies including BioChem Pharma Inc., Axcan Pharma Inc., Targeted Genetics Inc., and Idun Pharmaceuticals Inc.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• Director since 1998</li> <li>• Member of the Audit Committee (Chair)</li> <li>• Independent director</li> </ul>
 <p><b>Mattie Chinks, 61</b> Quebec, Canada Shares: 52,000<sup>(2)</sup> Options: 99,999</p>	<p>Mr. Chinks is President of Avmor Ltd., a company which manufactures institutional cleaning and maintenance chemical products, since 1996. Mr. Chinks has previously served as President and International Director of the International Sanitary Supply Association and currently sits on the Board of Directors of The Royal Victoria Hospital Foundation and Cannon Hygiene Canada.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• Director since April 2008</li> <li>• Member of the Human Resources and Remuneration Committee</li> <li>• Independent director</li> </ul>

 <p><b>Michel Lassonde, 69</b> Quebec, Canada Shares: 837,667<sup>(3)</sup> Options: 66,666</p>	<p>Mr. Lassonde has been a consultant and director of various companies since March 2008. Mr. Lassonde has also been President, CEO and Director of Fronsac Capital Inc. since August 2008. From September 1991 to March 2008, he was a Court of Québec judge. Previously, Mr. Lassonde practiced law for over 25 years. He has a master’s degree in international law from New York University.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• Director since April 2009</li> <li>• Member of the Corporate Governance Committee</li> <li>• Member of the Audit Committee (since May 11, 2010)</li> <li>• Independent director</li> </ul>
 <p><b>Patrice Hugo, 50</b> Quebec, Canada</p>	<p>Dr. Patrice Hugo has more than 20 years of experience in biomarkers including in the fields of discovery and validation as well as in diagnostic product development. Since 2009, he has been Chief Scientific Officer of Clearstone Central Laboratories, following the spin-off of a business unit of MDS Pharma Services to Global Central Laboratories where he held the position of Vice-President Scientific Affairs since 2008. From 2003 to 2008, Dr. Hugo held various senior roles at Caprion from Executive Director to Executive Vice President Research and Development. From 1997 to 2003, Dr. Hugo worked at PROCREA BioSciences, first as Vice President of Scientific Research and then as Chief Scientific Officer. From 1994 to 1997, he worked as a Principal Investigator at the Institut de Recherches Cliniques de Montréal. Dr. Hugo holds a PhD in Experimental Medicine from McGill University.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• New candidate for election to the Board of Directors</li> <li>• If elected, would be considered as an independent director</li> </ul>
 <p><b>Michael Singer, 46</b> Quebec, Canada</p>	<p>Mr. Singer has been Chief Financial Officer and Corporate Secretary of Thallion Pharmaceuticals Inc. since March 2007. Prior to Thallion, he served as Vice President, Chief Financial Officer and Corporate Secretary of Caprion Pharmaceuticals Inc. from February 2000 until its merger with Ecopia BioSciences Inc. to form Thallion in 2007.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• New candidate for election to the Board of Directors</li> <li>• If elected, would be considered as an independent director</li> </ul>
 <p><b>Marc LeBel, 56</b> Quebec, Canada</p>	<p>Mr. LeBel is currently Director of Acasti Pharma Inc., a member of the Advisory Committee of JustBio, Executive Producer of the film “Ruby McCollum”, and Associate Producer of the 3D animation movie “Sarila”. He is the founder of Anapharm Inc. and served as the company’s President from 1994 to 2007. Dr. LeBel was Executive Vice-President of Pharmanet, from 2005 to 2007, following its acquisition of Anapharm.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• New candidate for election to the Board of Directors</li> <li>• If elected, would be considered as an independent director</li> </ul>

 <p><b>Joseph Walewicz, 42</b> Quebec, Canada</p>	<p>Mr. Walewicz was Vice-President, Special Projects and COO of Paladin Biosciences between 2009 and 2011. Between 2005 and 2008, Mr. Walewicz was Executive Director, Institutional Equity Research at CIBC World Markets. Mr. Walewicz holds a Master of Business Administration, Finance, a Bachelor of Science, Biochemistry, and a Bachelor of Arts, Economics. Mr. Walewicz is also a CFA (Chartered Financial Analyst) charterholder.</p> <p><b>Board Details:</b></p> <ul style="list-style-type: none"> <li>• New candidate for election to the Board of Directors</li> <li>• If elected, would be considered as an independent director</li> </ul>
<p>(1) Of these Common Shares, 4,960,817 Common Shares are owned by Busgang Investments Inc., a company controlled by Mark Busgang, and 778,583 Common Shares are owned by Mark Busgang through his RRSP.</p> <p>(2) These Common Shares are held through a TFSA account controlled by Mr. Chinks.</p> <p>(3) Of these Common Shares, 610,000 Common Shares are owned by Michel Lassonde and 227,667 Common Shares are owned by Sofinat Ltd., a company controlled by Michel Lassonde.</p>	

The information as to the number of Common Shares beneficially owned or over which control is exercised, not being within the knowledge of the Corporation, has been provided by each nominee.

To the knowledge of Warnex and based on information provided by the nominees, with the exception of the facts disclosed below with respect to Mr. Laferrière, Mr. Lacasse, Mr. Busgang and Mr. Hugo:

- (a) no proposed director of our Corporation is, as at the date hereof or has been, within the 10 years before the date hereof, a director, chief executive officer or chief financial officer of any company, that,
  - (i) was the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than 30 consecutive days (an "Order") that was issued while the director or executive officer was acting in its capacity as director, chief executive officer or chief financial officer; or
  - (ii) was subject to an Order that was issued, after the director or executive officer ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer.
- (b) no proposed director of our Corporation:
  - (i) is, at the date hereof, or has been, within the 10 years before the date hereof, a director or executive officer of any company that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or was subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold its assets;
  - (ii) has, within 10 years before the date hereof, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or became subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director, executive officer or shareholder.

Mr. Laferrière was director of GlobeeCom International Inc., a corporation which, on May 1, 2006, announced that it would make a proposal to its creditors under the Bankruptcy and Insolvency Act in connection with a proposed reverse take over. The proposal to the creditors was accepted by the creditors on May 23, 2006. Shares of that corporation are not traded since April 27, 2006. The reverse take over has not yet been concluded. Mr. Laferrière was director of this corporation during the period of one year preceding its proposal.

Mr. Laferrière was Director and Chairman of the Board of FRV Media Inc., a corporation that was subject to a cease trade order from March 20, 2009, to April 20, 2009, for having failed to file its financial statements within the applicable delays, and from March 19, 2010 to May 4, 2010, for having failed to file its financial statements within the applicable delays. Following the filing of such documents, the cease trade orders were lifted.

Mr. Lacasse was a Director of Chromos Molecular Systems Inc. which was subject to a cease trade order from April 11, 2007 until July 22, 2008, as a result of the corporation submitting a Notice of Intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act.

Mr. Busgang was Chairman of the Board of Mistral Pharma Inc., which made a proposal to its creditors on June 13, 2008, under the Bankruptcy and Insolvency Act (BIA). The proposal included a reorganization of Mistral Pharma consisting in (i) the cancellation and annulment of all the existing shares and all the existing options and warrants of Mistral Pharma for all purposes, and (ii) the creation of a new class of common shares. On September 4, 2008, Mistral Pharma obtained creditor approval of its proposal. A final order of the Quebec Superior Court of Justice under the BIA was obtained on September 15, 2008. The common shares of Mistral Pharma were de-listed from the TSX Venture Exchange on September 30, 2008. Mr. Busgang was Chairman of this corporation during the period of one year preceding its proposal.

Dr. Hugo was Chief Scientific Officer of Procrea BioSciences, a Quebec Business Investment Company (QBIC), which terminated its operations in August 2003, when its major shareholder, Société Générale de Financement (SGF) du Québec, through a Court mandate, enforced its rights as creditor and, with its representative, Price Waterhouse Coopers, seized and sold all tangible and non-tangible assets of Procrea BioSciences.

## **D. DISCLOSURE OF COMPENSATION AND OTHER INFORMATION**

### **COMPENSATION OF DIRECTORS**

In fiscal 2010, all directors other than the Corporation's CEO were remunerated by the Corporation in their capacity as directors. Mark Busgang, President and CEO of the Corporation, received no remuneration as director. The compensation earned by Eric Veilleux, a nominee of SGF, was paid to SGF directly.

The compensation for the directors other than the Chairman of the Board is a combination of meeting fees and stock options. The meeting fees are further described in the chart below.

### **MEETING FEES PAYABLE TO DIRECTORS (OTHER THAN THE CHAIRMAN)**

<b>Detail</b>	<b>Compensation</b>
Fee for Board of Directors meeting attended	\$1,000
Fee for Board of Directors or Committee meeting attended by way of conference call	\$250
Fee for Board of Directors Committee meeting attended	\$1,000
Additional Fee for Committee Chairs (per meeting attended)	\$500

The Chairman of the Board is paid an annual retainer of \$24,000.

In accordance with the Corporation's present policy, each Director of the Corporation receives a certain number of stock options valued at \$5,000 annually upon his nomination or re-election to the Board of Directors. The price of each option is determined by the greater of \$0.15 or the closing trading price of the Corporation's common shares on the last trading day prior to the grant.

The total remuneration paid to directors (other than Mr. Busgang) during the fiscal year ended December 31, 2010, is set out in the following table:

#### REMUNERATION PAID TO DIRECTORS

Name	Fees earned (\$)	Option-based awards (\$)	All other compensation <sup>(1)</sup> (\$)	Total (\$)
Richard Laferrière	24,000	5,000 <sup>(2)</sup>	12,000 <sup>(3)</sup>	41,000
Louis Lacasse	11,500	5,000 <sup>(2)</sup>	nil	16,500
Jacques Gagné	8,750	5,000 <sup>(2)</sup>	nil	13,750
Gilles Gagnon	7,250	5,000 <sup>(2)</sup>	nil	12,250
Mattie Chinks	7,250	5,000 <sup>(2)</sup>	nil	12,250
Michel Lassonde	13,500	5,000 <sup>(2)</sup>	nil	18,500
Baljit Chadha	6,250	7,260 <sup>(4)</sup>	21,223 <sup>(5)</sup>	34,733
Richard Lacombe <sup>(6)</sup>	13,750	5,000 <sup>(2)</sup>	nil	18,750
Hubert Marleau <sup>(7)</sup>	2,000	nil	nil	2,000
Eric Veilleux <sup>(8)</sup>	3,000	nil	nil	3,000

(1) Other than as provided below with respect to Mr. Laferrière and Mr. Chadha, directors do not receive pension benefits, share-based awards, perquisites or other annual compensation.

(2) The value of the option-based awards is based on a value of \$0.15 per option, considering the Corporation's policy whereby options are issued on an annual basis in such quantity as to total a value of \$5,000, based on an exercise price which is the higher of \$0.15 and the actual trading price of the common shares of the Corporation on the TSX on the last trading date preceding the grant of the options.

(3) Mr. Laferrière received \$12,000 for consulting services provided to the Corporation, as further described in Section E "Interest of Insiders in Material Transactions" of this Information Circular.

(4) The value of the option-based awards is based on a value of \$0.15 per option, considering the Corporation's policy whereby options are issued on an annual basis in such quantity as to total a value of \$5,000, based on an exercise price which is the higher of \$0.15 and the actual trading price of the common shares of the Corporation on the TSX on the last trading date preceding the grant of the options. Mr. Chadha received a further grant of options on April 28, 2010 for a total value of \$2,863 for his participation to the Board of Directors during part of the previous year, as he joined the Board of Directors on October 1, 2009.

(5) Balcorp Ltd., a company owned by Mr. Chadha, received this amount as a sales commission, as further described in Section E "Interest of Insiders in Material Transactions" of this Information Circular.

(6) Mr. Lacombe joined the Corporation's Board of Directors on April 27, 2010.

(7) Mr. Marleau left the Corporation's Board of Directors on April 27, 2010.

(8) Mr. Veilleux left the Corporation's Board of Directors on April 27, 2010. Mr. Veilleux's compensation was paid to SGF Soquia directly.

The following table provides information on the number and value of each director's outstanding options at the end of the fiscal year.

#### OUTSTANDING DIRECTOR OPTION-BASED AWARDS

Name	Number of securities underlying unexercised options (#)	Option exercise price (\$)	Option expiration date	Value of unexercised in-the-money options <sup>(1)</sup> (\$)
<b>Richard Laferrière</b>				
- 2010 award	33,333	0.15	04/27/2020	0
- 2009 award	33,333	0.15	04/28/2019	0
- 2008 award	33,333	0.15	04/29/2018	0
- 2006 award	7,000	0.95	04/25/2016	0
- 2005 award	18,900	1.27	08/09/2015	0
- 2005 award	7,000	1.31	04/25/2015	0
- 2004 award	7,000	1.15	08/09/2014	0
- 2003 award	7,000	0.85	06/03/2013	0
<b>Louis Lacasse</b>				
- 2010 award	33,333	0.15	04/27/2020	0
- 2009 award	33,333	0.15	04/28/2019	0
- 2008 award	33,333	0.15	04/29/2018	0
- 2006 award	7,000	0.95	04/25/2016	0
- 2005 award	7,000	1.31	04/25/2015	0
- 2004 award	7,000	1.15	08/09/2014	0
- 2003 award	7,000	0.85	06/03/2013	0
- 2003 award	2,500	0.86	04/03/2013	0
<b>Hubert Marleau<sup>(2)</sup></b>				
	0	0	-	0
<b>Jacques Gagné</b>				
- 2010 award	33,333	0.15	04/27/2020	0
- 2009 award	33,333	0.15	04/28/2019	0
- 2008 award	33,333	0.15	04/29/2018	0
- 2006 award	7,000	0.95	04/25/2016	0
- 2005 award	7,000	1.31	04/25/2015	0
- 2004 award	7,000	1.15	08/09/2014	0
- 2003 award	7,000	0.85	06/03/2013	0
<b>Mattie Chinks</b>				
- 2010 award	33,333	0.15	04/27/2020	0
- 2009 award	33,333	0.15	04/28/2019	0
- 2008 award	33,333	0.15	04/29/2018	0
<b>Gilles Gagnon</b>				
- 2010 award	33,333	0.15	04/27/2020	0
- 2009 award	33,333	0.15	04/28/2019	0
- 2008 award	33,333	0.15	04/29/2018	0
<b>Michel Lassonde</b>				
- 2010 award	33,333	0.15	04/27/2020	0
- 2009 award	33,333	0.15	04/28/2019	0
<b>Baljit Chadha</b>				
- 2010 award	15,068	0.19	04/28/2020	0
- 2010 award	33,333	0.15	04/27/2020	0
<b>Richard Lacombe</b>				
- 2010 award	33,333	0.15	04/27/2020	0

(1) Calculation is based on the trading price of the Corporation's shares on the Toronto Stock Exchange of \$0.105 on December 31, 2010.

(2) As Mr. Marleau ceased being a director of the Corporation on April 27, 2010, his options lapsed 90 days later in accordance with the terms of the Corporation's Stock Option Plan.

The following table sets out the value of stock options vested or earned by the directors during the most recent completed financial year.

#### OPTIONS VESTED AND EARNED DURING THE YEAR

Name	Option-based awards – Value vested during the year (\$) <sup>(1)</sup>	Option-based awards – Value earned during the year (\$) <sup>(3)</sup>
Richard Laferrière	0	0
Louis Lacasse	0	0
Hubert Marleau	0	0
Jacques Gagné	0	0
Mattie Chinks	0	0
Gilles Gagnon	0	0
Michel Lassonde	0	0
Baljit Chadha	0 <sup>(2)</sup>	0
Richard Lacombe	0	0

(1) Each of these directors (except for Mr. Marleau) received a grant of 33,333 options on April 27, 2010 at an exercise price of \$0.15, and these options vested immediately upon their issuance. The aggregate dollar value that would have been realized if the options under the option-based award had been exercised on their vesting date is nil, based on the market price of the Corporation's shares on the TSX of \$0.12 on April 27, 2010.

(2) In addition, M. Chadha received a grant of 15,068 options on April 28, 2010 at an exercise price of \$0.19, and these options vested immediately upon their issuance. The aggregate dollar value that would have been realized if the options under the option-based award had been exercised on their vesting date is nil, based on the market price of the Corporation's shares on the TSX of \$0.12 on April 28, 2010.

(3) No options were exercised by directors during the financial year ended December 31, 2010.

#### COMPENSATION OF EXECUTIVE OFFICERS

This disclosure is intended to communicate the compensation provided to Mark Busgang, the Corporation's Chief Executive Officer ("CEO"), François Jetté, the Corporation's Chief Financial Officer ("CFO") and the three other most highly compensated executive officers of the Corporation (collectively, the "Named Executive Officers"). For 2010, these executives include: Dr. Michael Mancini, President, Warnex Bioanalytical Services, Dr. Yvan Côté, Vice-President and General Manager, Warnex Medical Laboratories, and Erik Yelle, Vice-President, Operations, Warnex Analytical Services.

The compensation of executive officers of the Corporation is recommended to the Board of Directors by the Human Resources and Remuneration Committee (the "HRRC"). In its review process, the HRRC relies on input from management on the assessment of executives and Company performance relative to plan. During the most recently completed fiscal year, the HRRC was composed of three directors, all of whom were independent directors, namely Dr. Jacques Gagné (chair), Mr. Éric Veilleux (until April 27, 2010), Mr. Mattie Chinks, and Mr. Baljit Chadha (since April 27, 2010). The HRRC establishes management compensation policies and oversees their general implementation. In addition, the HRRC monitors management succession planning and conducts periodic reviews of the overall condition and quality of the Corporation's human resources.

#### COMPENSATION DISCUSSION AND ANALYSIS

The Corporation's executive compensation program is intended to attract, motivate and retain high performing senior executives, encourage and reward superior performance and align the executives' interests with those of the Corporation by:

- Providing a compensation which is competitive with the compensation received by executives employed in the biotechnology and pharmaceutical industries;

- Ensuring that the achievement of annual objectives is rewarded through the payment of bonuses; and
- Providing executives with long-term incentive through the grant of stock options.

### *Benchmarking Practices*

The HRRC recognizes that the nature of the Corporation's business is highly competitive and that the ability to attract and retain dedicated and talented individuals with highly specialized skills and qualifications is critical to the Corporation's success. The salaries of executive officers have been established based on national surveys of the industry provided by independent consultants. For instance, the HRRC was provided with a survey performed by AON entitled "2006 Biotechnology Compensation Trends (Canada & USA)", which amongst other elements presents the average compensation of CEOs and CFOs in a group of 50 companies in the biotechnology industry, in Canada and in the United States, as well as a report prepared by Groupe Conseil SD specifically for the Corporation in March 2006, which provided an analysis of each of the Corporation's executive officer's remuneration as well as recommendations. These reports did not however list the comparable companies used to benchmark the compensation of executive officers.

### *Compensation Elements*

Remuneration of executive officers is revised each year and has been structured to encourage and reward the executive officers on the basis of short-term and long-term corporate performance. In the context of the analysis of the remuneration, the four following components are examined:

- (i) base salary;
- (ii) annual incentive plan, consisting of a bonus payable in cash or in stock options;
- (iii) grant of stock options of the Corporation; and
- (iv) other elements of compensation, consisting of benefits, perquisites and contribution to group RRSP.

### *Base Salary*

Salaries of the executive officers are established based on a general comparison with competitive market positions, without however any benchmark having been made with specific companies. In analyzing individual base salaries, the HRRC takes into consideration individual circumstances that may include the scope of an executive's position, the executive's relevant competencies and the executive's experience. The HRRC also takes into consideration the individual performance of the executive as well as the financial performance of the Corporation.

### *Annual Incentive Plan*

The Corporation has a bonus plan for the executive officers which is based on a percentage of their base salary. For the year 2010, the three operational executive officers, being Dr. Mancini, Dr. Côté and Mr. Yelle, had objectives based on attaining pre-established financial goals (revenue and EBITDA) for their respective division. These operational executive officers were eligible to receive a bonus payment in the event they attained at least 95% of their budgeted revenues or EBITDA, as further described in the following table.

## OPERATIONAL OFFICERS BONUS PROGRAM

Attainment of objectives (%)	Budgeted revenues	Budgeted EBITDA
95-99	10% of base salary	10% of base salary
100	17.5% of base salary	17.5% of base salary
Each incremental dollar	1.75% of incremental revenue \$	3.5% of incremental EBITDA \$

The following table sets forth the budgeted and actual results of revenues and EBITDA in each operational division, for the 2010 financial year.

## BUDGETED AND ACTUAL RESULTS OF OBJECTIVE PERFORMANCE GOALS

Division	Responsible Executive	Revenues (in thousands of \$)		EBITDA (in thousands of \$)	
		Budget	Actual	Budget	Actual
Analytical	Erik Yelle	12,965	10,597	1,981	632
Bioanalytical	Michael Mancini	8,030	6,426	2,056	1,427
Medical	Yvan Côté	5,354	5,167	1,125	1,138

Based on the achievement of budgeted revenues and EBITDA in their respective divisions for 2010, the operational officers were eligible to receive the bonuses set out in the following table.

## OPERATIONAL OFFICERS BONUS ELIGIBILITY

Name	Attainment of budgeted revenues (%)	Attainment of budgeted EBITDA (%)	Formula	Eligibility (\$)
Erik Yelle	82	32	-	-
Michael Mancini	80	69	-	-
Yvan Côté	97	101	$(10\% \times 186,299) + (17.5\% \times 186,299) + (13,721 \times 3.5\%)$	51,712

Dr. Côté was eligible to receive a bonus payment in the amount of \$51,712 for his performance in the 2010 fiscal year, but in light of the Corporation's overall financial performance in 2010, the Board of Directors exercised its discretion and no bonus was awarded to Dr. Côté.

Dr. Côté was eligible to receive a bonus payment in the amount of \$58,903 for his performance in the 2009 fiscal year (please refer to the Corporation's Information Circular for 2009, which may be consulted on SEDAR at [www.sedar.com](http://www.sedar.com)), but in light of the Corporation's overall financial performance in 2009, the Board of Directors exercised its discretion and no bonus was awarded to Dr. Côté at that time. On April 28, 2010, the Board of Directors awarded 392,687 options to Dr. Côté at an exercise price of \$0.15, for a total value of \$58,903, in lieu of the cash bonus he had been eligible to for 2009.

The CFO's bonus is discretionary and is based amongst other criteria on the Corporation's overall performance. Mr. Jetté's performance was reviewed by the CEO and by the HRRC. In light of the Corporation's overall financial performance in 2010, no bonus was awarded to Mr. Jetté.

As of the date of the Corporation's last Information Circular, it had been decided not to award any bonus to Mr. Jetté relative to his performance in 2009 in light of the Corporation's overall financial performance in 2009. On April 28, 2010, the Board of Directors made an exceptional award of 56,000 options to Mr. Jetté at an exercise price of \$0.15, in lieu of a bonus having a value of \$8,400, in light of his exceptional efforts and contribution during fiscal 2009.

Mr. Busgang's bonus entitlement for 2010 was a maximum of 40% of his base salary, based on the attainment of objectives pre-established by the HRRC. The following table sets out these objectives as pre-established by the HRRC.

### CEO OBJECTIVES FOR 2010

Percentage of Maximum Bonus Achievable (%)	Objective	Elements
70	Financial	<ul style="list-style-type: none"> <li>Meet or exceed consolidated budgeted goals for revenues and EBITDA</li> <li>Raise capital and restructure balance sheet to reduce overall debt</li> </ul>
30	Management and Operations	<ul style="list-style-type: none"> <li>Evaluate management (Levels 1, 2, 3) to insure that the right people are in the right seat.</li> <li>Manage direct reports to their stated objectives</li> <li>Assist in business development activities and the development of new markets and services</li> <li>Ensure that strategic planning becomes part of daily activities</li> <li>Participate in the evaluation, development and implementation of various management systems including ERP, CRM, LIMS</li> <li>Ensure ongoing compliance with best practices of corporate governance</li> <li>Develop new executive bonus plan including long-term incentive plan</li> <li>Ongoing development of KPI's and benchmarking</li> <li>Insure the optimal utilization of our assets</li> <li>Evaluate legal requirements and engage outside counsel as required to minimize risk</li> <li>Maintain external communications, participate in development of all marketing tools for corporate as well as operations</li> <li>Continue internal communications plan</li> <li>Begin investor relations program</li> </ul>
	Acquisitions	<ul style="list-style-type: none"> <li>Seek out and evaluate potential acquisitions that fit into the mission and focus of Warnex and close and integrate opportunities</li> <li>Evaluate new business opportunities</li> </ul> <p>The "acquisitions" item is not a formal objective but rather an additional item; if an acquisition is made during 2010, the Committee and the Board will consider awarding him an additional bonus.</p>

The following table sets forth the budgeted and actual results of consolidated revenues, EBITDA and profit for the 2010 financial year.

### BUDGETED AND ACTUAL RESULTS OF OBJECTIVE PERFORMANCE GOALS

Consolidated	Budget (in thousands of \$)	Actual (in thousands of \$)
Revenue	26,584	22,251
EBITDA	2,617	990
Profit (Loss)	151	(1,559)

The HRRC evaluated the above-mentioned objectives and considered that Mr. Busgang had met the "Management and Operations" objectives, but had not met the "Financial" objectives. On this basis, Mr. Busgang was eligible to receive a bonus in the amount of \$31,800 for the year 2010, being 30% of the maximum bonus Mr. Busgang was entitled to receive. However, in light of the Corporation's financial performance in 2010, the HRCC and the Board of Directors decided to award only half of this bonus

entitlement at the present time, and to award such bonus entitlement to Mr. Busgang through the issuance of 106,000 stock options of the Corporation at an exercise price of \$0.15, for a total value of \$15,900.

### *Stock Options*

The grant of stock options to the Corporation's executives is aimed at recognizing and rewarding the impact of longer-term strategic actions undertaken by management, offering an added incentive for the retention of the Corporation's executives as well as aligning the interests of the Corporation's executives with that of its shareholders.

For a more detailed description of the Corporation's Stock Option Plan, please refer to Page 20 of this Information Circular.

The Corporation's Human Resources and Remuneration Committee is responsible for overseeing and managing the Corporation's Stock Option Plan. Grants of options to executives are approved by the Corporation's Board of Directors. The Corporation's current policy on the award of stock options to executive officers is that they are entitled to receive a one-time grant of 75,000 stock options upon their hiring. The Corporation's Board of Directors is currently reviewing changes to this policy in order to make the grant of options a performance-based award.

On April 28, 2010, 56,000 options at an exercise price of \$0.15 were granted to François Jetté and 392,687 options at an exercise price of \$0.15 were granted to Yvan Côté, in lieu of a bonus for the 2009 fiscal year, as further described under the "Annual Incentive Plan" subsection of this Information Circular.

On May 26, 2011, 106,000 options at an exercise price of \$0.15 were granted to Mark Busgang in lieu of a bonus for the 2010 fiscal year, as further described under the "Annual Incentive Plan" subsection of this Information Circular.

### **OUTSTANDING OPTION-BASED AWARDS**

The following table sets out all awards of stock options outstanding to each Named Executive Officer as at December 31, 2010.

Name	Number of securities underlying unexercised options (#)	Option exercise price (\$)	Option expiration date	Value of unexercised in-the-money options <sup>(1)</sup> (\$)
<b>Erik Yelle</b>	75,000	1.10	04/14/2011 <sup>(2)</sup>	0
<b>Yvan Côté</b>				
- 2010 grant	392,687	0.15	04/28/2020	0
- 2005 grant	30,000	1.31	04/25/2015	0
- 2003 grant	45,000	0.84	09/03/2013	0
<b>François Jetté</b>				
- 2010 grant	56,000	0.15	04/28/2020	0
- 2005 grant	20,000	1.08	12/12/2015	0

(1) Calculation is based on the trading price of the Corporation's shares on the Toronto Stock Exchange of \$0.105 on December 31, 2010.

(2) Mr. Yelle left the Corporation on January 14, 2011, and his stock options lapsed 90 days following his departure.

**OPTIONS VESTED AND EARNED DURING THE YEAR**

The following table sets forth the value of options based-awards vested and earned during the 2010 financial year.

Name	Option-based awards – Value vested during the year (\$)	Option-based awards – Value earned during the year (\$) <sup>(4)</sup>
Erik Yelle	0 <sup>(1)</sup>	0
Yvan Côté	0 <sup>(2)</sup>	0
François Jetté	0 <sup>(3)</sup>	0

(1) All options held by Mr. Yelle had vested prior to the 2010 financial year.  
(2) Mr. Côté received a grant of 392,687 options on April 28, 2010 at an exercise price of \$0.15, and these options vested immediately upon their issuance. The aggregate dollar value that would have been realized if the options under the option-based award had been exercised on their vesting date is nil, based on the market price of the Corporation's shares on the TSX of \$0.12 on April 28, 2010. All other options held by Mr. Côté have vested prior to the 2010 financial year.  
(3) Mr. Jetté received a grant of 56,000 options on April 28, 2010 at an exercise price of \$0.15, and these options vested immediately upon their issuance. The aggregate dollar value that would have been realized if the options under the option-based award had been exercised on their vesting date is nil, based on the market price of the Corporation's shares on the TSX of \$0.12 on April 28, 2010. All other options held by Mr. Jetté have vested prior to the 2010 financial year.  
(4) No options were exercised by Named Executive Officers during the financial year ended December 31, 2010.

*Other Forms of Compensation*

The Corporation's employee benefit program, which applies to all employees including the Named Executive Officers, includes life, medical, dental and disability insurance. Perquisites provided to Named Executive Officers consist of a car allowance and an annual health assessment, and in addition, the CEO receives compensation relative to club memberships. These benefits and perquisites are considered as being regular perquisites for high-level executives. Due to the payment of the car allowance, the Named Executive Officers do not claim any reimbursement for mileage when using their car for in the performance of their work for the Corporation. The Corporation encourages its Named Executive Officers to undergo annual health assessments which it considers is in the best interest of both the Named Executive Officer and the Corporation.

Under the Corporation's retirement savings program, all salaried employees including the Named Executive Officers of the Corporation receive a contribution in their Registered Retirement Savings Plan ("RRSP") equal to 1% of their base annual salary, with no matching required.

**SUMMARY COMPENSATION TABLE**

The following Summary Compensation Table sets forth the compensation information for the Named Executive Officers for services rendered during the year ended December 31, 2010.

For compensation related to previous years, please refer to the Corporation's previous Information Circulars available at [www.sedar.com](http://www.sedar.com).

## SUMMARY COMPENSATION TABLE – NAMED EXECUTIVE OFFICERS

Name and Principal Position	Year	Salary (\$)	Option-based awards (\$)	Annual incentive plans (\$)	All other compensation (\$)	Total compensation (\$)
Mark Busgang President and Chief Executive Officer	2010	241,923 <sup>(1)</sup>	15,900 <sup>(2)</sup>	0	30,444 <sup>(3)</sup>	288,267
	2009	263,144	0	0	77,332	340,476
	2008	233,156	0	96,350	60,332	359,838
Yvan Côté Vice President and General Manager, Warnex Medical Laboratories	2010	186,300	58,903 <sup>(4)</sup>	0	14,888 <sup>(5)</sup>	260,091
	2009	185,431	0	0	14,879	200,310
	2008	171,306	0	63,700	14,738	249,744
Michael Mancini President, Warnex Bioanalytical Services	2010	225,000	0	0	15,275 <sup>(5)</sup>	240,275
	2009	223,461	0	0	15,260	238,721
	2008	205,000	0	172,655	15,075	392,730
Erik Yelle <sup>(6)(7)</sup> Vice President, Operations, Warnex Analytical Services	2010	163,593	0	0	14,888 <sup>(5)</sup>	178,481
	2009	185,815	0	0	14,883	200,698
	2008	180,000	0	0	14,825	194,825
François Jetté Chief Financial Officer <sup>(8)</sup>	2010	140,000	8,400 <sup>(9)</sup>	0	14,425 <sup>(5)</sup>	162,825
	2009	138,385	0	0	8,409	146,794
	2008	115,203	0	23,800	8,177	147,180

(1) Mr. Busgang took a voluntary reduction of \$25,000 in his base salary during the 2010 financial year in light of the Corporation's financial position.

(2) On May 26, 2011, the Board of Directors decided to award to Mr. Busgang options having a value of \$15,900, in lieu of a bonus which was earned and would otherwise be payable in cash. Based on the Corporation's unwritten policy to award options at a price not less than \$0.15, the Board of Directors awarded to Mr. Busgang 106,000 options at an exercise price of \$0.15, as further described in this Information Circular.

(3) This amount represents perquisites and other personal benefits for the 2010 fiscal year, and includes \$15,000 in club memberships and \$12,000 in car allowance.

(4) On April 28, 2010, the Board of Directors decided to award Dr. Côté options having a value of \$58,903, in lieu of the bonus which was earned but not paid, at the Board's discretion, in 2009. Based on the Corporation's unwritten policy to award options at a price not less than \$0.15, the Board of Directors awarded to Dr. Côté 392,687 options at an exercise price of \$0.15, as further described in this Information Circular.

(5) This amount represents perquisites and other personal benefits during the given fiscal year, and includes \$12,000 in car allowance.

(6) Mr. Yelle left the Corporation on January 14, 2011.

(7) On January 14, 2011, the Corporation agreed to pay to Mr. Yelle an amount representing nine months of his annual base salary, namely \$139,725, payable as follows: \$93,150 in salary continuance for the six month period beginning January 17, 2011 and ending July 15, 2011, and a lump sum amount of \$46,575, representing three months of base salary, payable on July 21, 2011. The Corporation agreed to continue to contribute to Mr. Yelle's Group RRSP, and Mr. Yelle may continue to participate in the Corporation's Group Insurance Plan (except for disability insurance), until the earlier of: (i) July 15, 2011, and (ii) the date on which Mr. Yelle commences employment with a new employer. The Corporation agreed to continue to pay to Mr. Yelle a car allowance as follows: (i) \$1,000 per month until June 30, 2011, and (ii) \$3,500 on July 15, 2011.

(8) Mr. Jetté became CFO on April 1, 2008. Prior to this, he was Corporate Controller for the Corporation.

(9) On April 28, 2010, the Board of Directors decided to award Mr. Jetté options having a value of \$8,400, in lieu of a cash bonus for his contribution in the 2009 fiscal year. Based on the Corporation's unwritten policy to award options at a price not less than \$0.15, the Board of Directors awarded to Mr. Jetté 56,000 options at an exercise price of \$0.15, as further described in this Information Circular.

**TERMINATION AND CHANGE OF CONTROL BENEFITS**

The Corporation is party to an employment agreement with Mark Busgang, Michael Mancini and Yvan Côté, and was party to an employment agreement with Erik Yelle, who left the Corporation on January 14, 2011.

Mr. Busgang's employment agreement provides that in the event the employee is terminated without cause, the Corporation must pay to the employee a compensation in lieu of notice equivalent to the total remuneration received by the employee during the fifteen months preceding the termination (including base salary, bonus, discretionary expense account, car allowance and other benefits including the group insurance plan, retirement saving plan, membership fees) as well as the bonus for the fiscal year during which the termination occurs, prorated based on the number of months worked during the said fiscal year. In addition, it provides that he be entitled to receive 24 months of total remuneration in the event of a change of control of the Corporation.

Dr. Mancini and Dr. Côté's employment agreements provide that in the event the employee is terminated without cause, the Corporation must pay to the employee a compensation in lieu of notice equivalent to twelve months of salary (including base salary, bonus, discretionary expense account, car allowance and other benefits including the group insurance plan, retirement saving plan, membership fees) as well as the bonus for the fiscal year during which the termination occurs, prorated based on the number of months worked during the said fiscal year.

Mr. Yelle's employment agreement provided that in the event the employee is terminated without cause, the Corporation must pay to the employee a compensation in lieu of notice equivalent to twelve months of salary (including base salary, bonus, discretionary expense account, car allowance and other benefits including the group insurance plan, retirement saving plan, membership fees) as well as the bonus for the fiscal year during which the termination occurs, prorated based on the number of months worked during the said fiscal year. Since Mr. Yelle's departure from the Corporation was made by mutual consent between Mr. Yelle and the Corporation, the conditions attaching to this termination of employment was negotiated between the parties. The Corporation agreed to pay to Mr. Yelle an amount representing nine months of his annual base salary, namely \$139,725, payable as follows: \$93,150 in salary continuance for the six month period beginning January 17, 2011 and ending July 15, 2011, and a lump sum amount of \$46,575, representing three months of base salary, payable on July 21, 2011. The Corporation agreed to continue to contribute to Mr. Yelle's Group RRSP, and Mr. Yelle may continue to participate in the Corporation's Group Insurance Plan (except for disability insurance), until the earlier of: (i) July 15, 2011, and (ii) the date on which Mr. Yelle commences employment with a new employer. The Corporation agreed to continue to pay to Mr. Yelle a car allowance as follows: (i) \$1,000 per month until June 30, 2011, and (ii) \$3,500 on July 15, 2011. Such payments were made and will be made during the 2011 financial year and therefore do not appear in this Information Circular's Summary Compensation Table (other than as disclosed in a footnote).


The following table shows estimated incremental payments triggered pursuant to a change of control of the Corporation in accordance with the change of control provisions described above.

Position	Incumbent	Termination Provisions Value (1)(2)(3) (\$)	Change of Control Provisions Value <sup>(1)(2)(3)</sup> (\$)
President and CEO	Mark Busgang	432,305	691,687 <sup>(4)</sup>
Vice-President and General Manager, Warnex Medical Laboratories	Yvan Côté	259,258	-
President, Warnex Bioanalytical Services	Michael Mancini	299,802	-

(1) The values assume that the triggering event took place on the last business day of the Corporation's fiscal year-end (December 31, 2010).  
(2) Should the termination have occurred on December 31, 2010, no option-based awards would have been payable.  
(3) Value of earned/unused vacation and owed expense are not included as they are not considered as "incremental" payments further to termination.  
(4) In the event of a termination due to a change of control, Mr. Busgang is entitled to receive the equivalent of 24 months of total remuneration in lieu of (and not in addition to) the 15-month notice which applies for other cases of termination without cause.

## PERFORMANCE GRAPH

The following graph compares the cumulative total shareholder return for a \$100 investment in Common Shares of the Corporation made on December 31, 2005, on the Toronto Stock Exchange and the cumulative total return of the S&P/TSX Small Cap index, the TSX Biotechnology index (available until 2007) and the TSX Life Sciences Tools and Services index (available since 2006).



There is little correlation to be made between the trend shown by this graph and the trend in the Corporation's compensation to executive officers reported under this form. The Corporation's executive compensation, with the exception of stock options, is based on the Corporation's performance rather than on the Corporation's share price.

## EQUITY COMPENSATION PLANS

The following table sets forth compensation plans under which equity securities of the Corporation are authorized for issuance, being the Corporation's Stock Option Plan, as at December 31, 2010:

Plan Category	Number of securities to be issued upon exercise of outstanding options (a)	Weighted-average exercise price of outstanding options (b) (\$)	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)
Equity compensation plans approved by security holders	1,852,711	0.35	2,466,562
Equity compensation plans not approved by security holders	None	-	-

### Stock Option Plan

The Corporation has adopted the 2003 Stock Option Plan (the "Stock Option Plan") for the Directors, officers, employees and consultants of the Corporation and its subsidiaries, as designated by the Board of Directors of the Corporation or the Human Resources and Remuneration Committee, pursuant to which options to purchase an aggregate of 4,319,273 common shares, which represent, on May 17, 2011, 6.4% of all issued and outstanding common shares, may be granted.

The number of Common Shares covered by any stock option, the exercise price, expiry date and vesting period of such stock option and any other matter pertaining thereto are determined by the Board of Directors of the Corporation or the Human Resources and Remuneration Committee. Options granted are non-assignable except if the assignment is approved by the Human Resources and Remuneration Committee or the Board of Directors, the assignee is an "Authorized Assignee" under the terms of the Plan, no compensation is made during the course of the assignment and the assignment conforms to the applicable policies of the Stock Exchange. No single person may be granted options covering more than 5% of the Corporation's issued and outstanding Common Shares. Options are fully exercisable by the optionee's legal representative, in the case of death or physical or mental disability of the optionee within a period of one year thereafter. Otherwise, options will lapse upon termination of employment or the end of the business relationship with the Corporation except that they may be exercised for 90 days after termination or the end of the business relationship, to the extent that they will have vested on such date.

No option may be allotted for a period exceeding 10 years and the exercise price of each stock option is equal to the market price of the share at the close of business of the exchange on the date immediately preceding the grant. Unless the Board of Directors or the Human Resources and Remuneration Committee decides otherwise, each option granted pursuant to the Plan will vest in three annual and equal tranches from the date of its grant and at each of the two subsequent anniversaries. Notwithstanding the foregoing, if the Corporation is sold, all the options that are not vested at the time of the sale will become vested and may be exercised by the optionees. The Plan also provides for the adjustment of the number and price of the stock options in the case of reorganization, merger, subdivision and consolidation of the shares and in other situations defined in the Plan. In some of these situations, the approval of the Toronto Stock Exchange and/or the shareholders of the Corporation may have to be obtained. The Board of Directors of the Corporation has the right to amend the Plan, subject to amendments which require the approval of the Toronto Stock Exchange or of the shareholders of the Corporation in accordance with the applicable rules and regulations.

## **E. OTHER INFORMATION**

### **REPORT OF THE CORPORATE GOVERNANCE COMMITTEE**

The Board of Directors and the management of the Corporation believe that good corporate governance is an important factor in the Corporation's overall success and in enhancing shareholder value. The following disclosure sets out the Corporation's corporate governance practices.

#### **Mandate, Structure and Composition of the Corporation's Board of Directors**

The Corporation's Board of Directors currently consists of nine (9) members. Five (5) of these members are proposed for re-election as directors for the ensuing year, and, in addition, four (4) new candidates are proposed for election as director.

##### *Corporate Governance Manual*

The Board of Directors has adopted a Corporate Governance Manual, which includes the mandate of the Board of Directors and of each of its committees, position descriptions for the Chairman of the Board of Directors, for the President and Chief Executive Officer of the Corporation and for each of the Committee Chairs, as well as the Corporation's Code of Ethics, its Communications Policy, and its Procedures for Complaints and Concerns Regarding Accounting, Internal Accounting Controls, Auditing and Other Matters. The Audit Committee Charter and the mandate of the Board of Directors are reproduced as Schedules A and B, respectively, of the Corporation's *2010 Annual Information Form*, which may be consulted on SEDAR at [www.sedar.com](http://www.sedar.com).

##### *Director Independence*

The Corporation considers that the majority of its Board of Directors, being 8 out of its 9 directors, are independent as defined in Multilateral Instrument 52-110. The Board of Directors has determined that the directors identified as being independent in this Information Circular do not have a direct or indirect relationship with the Corporation that could reasonably interfere with the Directors' ability to exercise their independent judgment, and that they are therefore independent under the applicable guidelines and rules. Mark Busgang is considered as a related director due to his position as President and CEO of the Corporation.

The Corporation also considers that the four new candidates for election to the Board of Directors, being Mr. Hugo, Mr. Singer, Mr. Walewicz and Mr. LeBel, are considered independent as defined in Multilateral Instrument 52-110.

The Board of Directors holds meetings regularly without the presence of members of management and of Mark Busgang, President, CEO and Director, following the Corporation's scheduled Board meetings. In 2010, the Board of Directors met on four occasions without members of management and Mr. Busgang's presence.

The mandate of the Board of Directors and the Charters of each committee provide that any individual director may engage outside advisors at the expense of the Corporation, with the prior approval of the Corporate Governance Committee, and each committee may also engage outside legal counsel or accountants or any other expert required to complete a specific mandate.

### Standing Committees

The Board has delegated responsibilities to three standing committees, being the Corporate Governance Committee, the Human Resources and Remuneration Committee and the Audit Committee. The following table sets forth the responsibilities of each standing committee of the Corporation's Board of Directors.

#### COMMITTEE RESPONSIBILITIES

Committee	Membership
<p><b>Corporate Governance Committee</b> Composed entirely of independent directors, the Corporate Governance Committee is responsible for:</p> <ul style="list-style-type: none"> <li>• ensuring that adequate policies and procedures relating to corporate governance are adopted by the Corporation and disseminated to its employees where appropriate;</li> <li>• evaluating the role of the various committees of the Board and recommending to the Board changes to these committees;</li> <li>• evaluating the size, composition and conduct of the Board of Directors as well as the contribution of each individual director;</li> <li>• presenting to the Board candidates for nomination as director and reviewing the nominees for re-election before each annual meeting;</li> <li>• developing the Corporation's annual disclosure relating to its corporate governance practices.</li> </ul>	<p>Richard Laferrière (Chair) Dr. Jacques Gagné Michel Lassonde</p>
<p><b>Human Resources and Remuneration Committee</b> Composed entirely of independent directors, the Human Resources and Remuneration Committee is responsible for:</p> <ul style="list-style-type: none"> <li>• evaluating the remuneration of the Corporation's senior executives, having regard for competitive position and individual performance, and making recommendations to the Board, which makes the final determination of the compensation of the senior executives;</li> <li>• evaluating and recommending to the Board of Directors remuneration policies for directors;</li> <li>• establishing the overall policies for remuneration of employees as well as the establishment and evaluation of the bonus program and the Corporation's stock option plan;</li> <li>• ensuring that the organization plan of the Corporation is consistent with its strategic plan, and that the appropriate training and succession plans are in place to ensure the continuing success of the Corporation.</li> </ul>	<p>Dr. Jacques Gagné (Chair) Eric Veilleux (until April 27, 2010) Mattie Chinks Baljit Chadha (since April 27, 2010)</p>
<p><b>Audit Committee</b> Composed entirely of independent directors, the Audit Committee is responsible for:</p> <ul style="list-style-type: none"> <li>• reviewing and recommending to the Board the selection of the Corporation's independent auditors as well as the compensation to be paid to such auditors;</li> <li>• reviewing with the independent auditors the scope of their audit;</li> <li>• discussing with management and the independent auditors the adequacy and effectiveness of the accounting and financial controls;</li> <li>• overseeing the work of the external auditor;</li> <li>• reviewing the Corporation's financial statements, MD&amp;A and annual and interim press releases;</li> <li>• reviewing the Corporation's insurance program.</li> </ul> <p>The Corporation's audit committee charter is reproduced as Schedule A of the Corporation's 2010 Annual Information Form, which may be consulted on SEDAR at <a href="http://www.sedar.com">www.sedar.com</a>.</p>	<p>Louis Lacasse (Chair) Eric Veilleux (until April 27, 2010) Gilles Gagnon Michel Lassonde (since May 11, 2010) Richard Lacombe (since April 27, 2010)</p>

## Attendance at Board and Committee Meetings

The overall attendance rate for the Corporation's Board of Directors meetings for fiscal 2010 was 91% for the Board of Directors, 100% for the Audit Committee, 100% for the Human Resources and Remuneration Committee and 100% for the Corporate Governance Committee. The following table sets forth the attendance of Directors at Board and Committee meetings in 2010:

### BOARD AND COMMITTEE MEETINGS AND ATTENDANCE FOR THE YEAR ENDED DECEMBER 31, 2010

	Number of Board Meetings Held in 2010		Number of Committee Meetings Held in 2010 AUD: 4 meetings GOV: 1 meeting HR: 1 meeting	
	7 meetings			
Director	Board Meetings Attended		Committee Meetings Attended	
Richard Laferrière	6 of 7	86%	1 of 1 (GOV) (Chair)	100%
Mark Busgang	7 of 7	100%	N/A	N/A
Louis Lacasse	7 of 7	100%	4 of 4 (AUD) (Chair)	100%
Hubert Marleau <sup>(1)</sup>	1 of 1	100%	1 of 1 (AUD)	100%
Jacques Gagné	6 of 7	86%	1 of 1 (GOV) 1 of 1 (HR) (Chair)	100% 100%
Eric Veilleux <sup>(2)</sup>	1 of 1	100%	1 of 1 (AUD) 1 of 1 (HR)	100% 100%
Gilles Gagnon	6 of 7	86%	4 of 4 (AUD)	100%
Mattie Chinks	4 of 7	57%	1 of 1 (HR)	100%
Michel Lassonde	7 of 7	100%	1 of 1 (GOV) 3 of 3 (AUD)	100% 100%
Baljit Chadha	6 of 7	86%	N/A	N/A
Richard Lacombe <sup>(3)</sup>	6 of 6	100%	4 of 4 (AUD)	100%
<b>Committees:</b> (AUD): Audit Committee (HR): Human Resources and Remuneration Committee (GOV): Corporate Governance Committee				
(1) Mr. Marleau left the Board of Directors on April 27, 2010. (2) Mr. Veilleux left the Board of Directors on April 27, 2010. (3) Mr. Lacombe joined the Board of Directors on April 27, 2010.				

## Role and Responsibilities of the Chairman of the Board of Directors, of the President and CEO and of Each Committee Chair

The Board of Directors has developed written position descriptions for the Chairman of the Board and of each committee as well as for the President and CEO.

### *Chairman of the Board*

The Chairman of the Board of Directors, Richard Laferrière, is an independent director. His role is to be responsible for the proper functioning of the Board of Directors, for its composition subject to shareholders' approval, for guiding discussions for strategic decision-making and for supervising the implementation of

decisions made by the Board and its committees.

In fulfilling his responsibilities, the Chairman collaborates with the CEO in the establishment of agendas for Board meetings and in ensuring that all important strategic questions are dealt with by the Board.

#### *President and CEO*

In addition to the items mentioned above where the President and CEO and the Chairman collaborate, the President and CEO's responsibilities include the elaboration and execution of the strategies and policies of the Corporation, including the Corporation's organizational chart, business plans and budgets, and representing the Corporation before the Corporation's shareholders, financial partners, the government and the public.

#### *Committee Chairs*

Each of the Committee Chairs must be independent directors. Their responsibilities include the management of the Committee's business, providing input to the Corporation's management on the preparation of agendas, guiding meetings to ensure the Committee fulfills its mandate as stated in its charter, reporting to the Board on all matters of importance discussed by the Committee and making recommendations in accordance with the Committee's charter and the Corporation's level of authority policy.

In addition, the Chair of the Audit Committee is responsible for overseeing the Corporation's "Procedure for Complaints and Concerns Regarding Accounting, Internal Accounting Controls, Auditing and Other Matters" and receiving and treating complaints in accordance with this Procedure.

### **Nomination of Directors**

The members of the Corporate Governance Committee and the CEO are responsible for identifying potential new Board Members from the business community who meet the required skill sets. These skill sets are defined annually in the assessment questionnaires further discussed below.

The Corporate Governance Committee is responsible for recommending to the Board of Directors candidates for nomination as director and for reviewing the nominees for re-election before each annual meeting. In collaboration with the CEO, the Chairman of the Board, who is also Chairman of the Corporate Governance Committee, studies candidatures for new directors and suggests candidates to the Corporate Governance Committee.

As part of its mandate, the Corporate Governance Committee evaluates the skills and competencies of the Board as a whole, as well as the contribution each director brings to the Board for the direction of the Corporation's business and affairs. The Board of Directors has implemented a process by which this assessment is performed on an annual basis by all directors, individually, through a detailed questionnaire. This process provides useful information to the Corporate Governance Committee to help assess the profile of future director candidates.

### **Orientation of New Directors and Continuing Education**

The Board of Directors has adopted a process for the orientation of new directors, which includes a meeting with the President and CEO to discuss the nature and operation of the Corporation's business, a tour of the Corporation's installations, providing new directors with the Corporation's strategic plan and Corporate Governance Manual, and offering them a copy of the minutes of the Board of Directors' meetings for the preceding twelve months. Detailed annual Board and Audit Committee meeting schedules for the ensuing year are provided to all new directors and are reviewed and updated on an ongoing basis.

The Corporation does not provide its directors with a continuing education program to ensure they maintain the skill and knowledge necessary to meet their obligations as directors. However, all directors possess considerable experience and skills in the business, finance and /or scientific industries. In addition, during their regularly scheduled Board meetings, presentations are made to the directors on various aspects of the Corporation's business as well as on legal and regulatory developments relevant to the Corporation. In addition, every year, special strategic meetings of the Board of Directors are held to discuss the Corporation's plan and budget for the following financial year as well as its execution of the Corporation's strategic plan.

### **Compensation of Directors and Officers**

The Human Resources and Remuneration Committee is responsible for evaluating the remuneration of the Corporation's senior executives, having regard for competitive position and individual performance, and making recommendations to the Board, which makes the final determination of the compensation of the senior executives. With respect to the President and CEO, the Human Resources and Remuneration Committee recommends to the Board of Directors his annual performance objectives and evaluates his performance in light of these objectives.

The Human Resources and Remuneration Committee also evaluates and recommends to the Board of Directors remuneration policies for directors, with a view of ensuring that it realistically reflects the responsibilities and risks involved in being a director of the Corporation. A summary of the compensation received by directors for the financial year ended December 31, 2010, is provided in this Information Circular under the heading "D. Director and Executive Compensation".

In 2006, the Corporation retained the services of Groupe Conseil SD, compensation consultants, who have proceeded to a review of the senior executives' compensation program as well as a review of the Corporation's Canadian and American group insurance program. Groupe Conseil SD have reported their findings to the Human Resources and Remuneration Committee.

### **Assessments**

Annually, a detailed questionnaire is addressed to each director, in his or her capacity as director, and, as the case may be, as a member of one or more of the committees of the Board of Directors, aimed at obtaining their views on the effectiveness of the Board and of its committees. The results of the questionnaires are compiled and remitted to the Corporate Governance Committee, which reviews and discusses any and all issues and reports to the Board on its findings. The Board of Directors reviews the results of these questionnaires and the recommendations provided by the Corporate Governance Committee and takes appropriate action based upon the results of the review process. The Board has also implemented individual director performance assessments, which is conducted and reviewed annually.

### **Ethical Business Conduct**

The Board of Directors has adopted a Code of Ethics, which provides guidelines to ensure that all directors, officers and employees of the Corporation and all consultants and other persons working on behalf of the Corporation respect its commitment to conduct business relationships with the highest standards of ethical conduct.

The Board of Directors is responsible for monitoring compliance to the Code of Ethics. The CFO, the CEO and the committees are each responsible for reporting to the Board any failure to comply with the Code of Ethics, and the Board has the ultimate responsibility of addressing such failures. In addition, the Code of Ethics provides that each of the Corporation's employees is obligated to communicate any situation that raises

a question as to ethical or legal compliance. The Corporation has not filed any material change report pertaining to a conduct of a director or officer that would constitute a departure from the Code of Ethics. An updated version of the Corporation's Code of Ethics was filed on SEDAR on March 14, 2008, and may be consulted at [www.sedar.com](http://www.sedar.com).

The Corporation has also established procedures approved by the Audit Committee for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls, auditing or other matters. In accordance with this policy, any person who wishes to submit a complaint may do so by sending it to the attention of CEO or the Chair of the Audit Committee.

The Code of Ethics and the Procedure for Complaints and Concerns Regarding Accounting, Internal Accounting Controls, Auditing and Other Matters were presented to all of the Corporation's employees, who have provided a written acknowledgement confirming that they have received a copy of these documents and that they undertake to comply with them.

At each of its regularly scheduled meetings, the Board of Directors enquires to management and to the Chairman of the Audit Committee if they have received any complaint with respect to matters addressed by the Code of Ethics and by the Procedures for Complaints and Concerns Regarding Accounting, Internal Accounting Controls, Auditing and Other matters.

#### **DIRECTORS' AND OFFICERS' LIABILITY INSURANCE**

The Corporation provides, at its sole cost, liability insurance for its Directors and officers covering them against liability arising while engaged in those capacities by means of insurance policies which also cover the Directors and officers of the Corporation's subsidiaries, if any. During the fiscal year ended December 31, 2010, the policy provided maximum coverage of \$5,000,000 per occurrence and a maximum coverage of \$5,000,000 per each policy period subject to a deductible of \$25,000 per occurrence for the Corporation. The premium paid for the policies was \$22,475. Neither the policies nor the premium paid make any distinction between the liability insurance for the Corporation's Directors and officers, since the coverage is the same for both groups.

#### **INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON**

Other than as set forth in this Information Circular, management of the Corporation is not aware of any material interest, direct or indirect, of any Director, officer or any associate or affiliate of any of the foregoing persons, in any matter to be acted upon, other than the election of Directors.

#### **INDEBTEDNESS OF DIRECTORS AND OFFICERS**

No Director, officer, nor any of their respective associates or affiliates is or has been at any time since the date of incorporation indebted to the Corporation.

#### **INTEREST OF INSIDERS IN MATERIAL TRANSACTIONS**

Management of the Corporation is not aware of any material interest, direct or indirect, of any insider of the Corporation, or any associate or affiliate of any such person in any transaction during the financial year ended December 31, 2010, or in any proposed transaction, that has materially affected or would materially affect the Corporation or any of its subsidiaries. However, while management does not believe the following interests to be material in nature, it wishes to make the following disclosure relating to transactions between the Corporation and the following directors.

The Corporation paid \$12,000, being \$1,000 per month, to the Corporation's Chairman of the Board, Richard Laferrière, for his work on specific mandates for the various operating divisions of the Corporation.

In 2010, a sales commission in the amount of \$21,223 was paid to Balcorp Ltd., a company owned by Baljit S. Chadha, a member of the Corporation's Board of Directors.

**GENERAL**


Except as otherwise mentioned, the information contained herein is given as of the 17<sup>th</sup> day of May 2011.

**ADDITIONAL INFORMATION**

Additional financial and other information relating to the Company is included in its 2010 audited annual and unaudited quarterly financial statements, annual and quarterly Management's Discussion and Analysis, Annual Information Form and other continuous disclosure documents, which are available on SEDAR at [www.sedar.com](http://www.sedar.com) and on the Corporation's website at [www.warnex.ca](http://www.warnex.ca).

**APPROVAL OF THE DIRECTORS**

The Directors of the Corporation have approved the content and mailing of this Information Circular to the shareholders, Directors and auditors of the Corporation.

A handwritten signature in black ink, appearing to read 'Mark Busgang', with a long horizontal flourish extending to the right.

Mark Busgang  
President and CEO  
Laval, May 17, 2011



Warnex Inc.  
3885 Industriel Blvd.  
Laval (Quebec), Canada H7L 4S3  
Tel: (450) 663-6724  
Fax: (450) 669-2784  
[info@warnex.ca](mailto:info@warnex.ca)  
[www.warnex.ca](http://www.warnex.ca)